Fig. 1From: Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trialsFlowchart of patient disposition. FAS full analysis set, HBV DNA hepatitis B virus DNA, MTX methotrexateBack to article page